Literature DB >> 28273960

Unusual Dyslipidemia in Patients with Chronic Kidney Diseases.

Rashmi Rekha Phukan1, Rohini K Goswami2.   

Abstract

INTRODUCTION: Chronic Kidney Disease (CKD) is a major and globally increasing health problem in the general population arising from a spectrum of diseases. Majority of the patients die even before reaching End Stage Renal Disease (ESRD) due to cardiovascular complications which arise due to altered lipoprotein compositions. AIM: Present study was aimed at evaluating the serum lipid profile in CKD patients and to find the pattern of its alteration in both haemodialyzed and conservatively treated CKD patients.
MATERIALS AND METHODS: Seventy one randomly selected CKD patients attending a tertiary care hospital of Assam during one year of time frame (40 haemodialyzed and 31 conservatively treated) along with 50 apparently healthy controls were included in the study. Test for serum lipid profile, urea creatinine, FBS, PPBS, total protein and albumin were carried out in all the cases and controls. The results were analyzed and compared with the controls using Microsoft Excel software.
RESULTS: Triglyceride Level (TGL) of CKD group 157.88±61.82, controls 96.98±37.52, Very Low Density Lipoprotein (VLDL) of CKD group 31.58±12.36, controls 19.39±7.50 was marginally elevated and High Density Lipoprotein (HDL) of CKD group 33.40±9.06, controls 45.95±10.35 was significantly reduced in the patient group as compared to the controls and the results were statistically highly significant with p-value<0.001. Total cholesterol (CKD group 128.2±53.57, controls 142.53±31.44) and LDL (CKD group 63.23±46.47, controls 77.35±26.81) were lower in the patient group as compared to the controls, however the difference was statistically not significant (p value 0.09 and 0.059 respectively). There was no statistically significant difference of lipid profile between hemodialyzed and conservatively treated CKD groups and there was no gender related variation of lipid profile too.
CONCLUSION: Increased TGL and reduced HDL, rather than increased total cholesterol and increased LDL are responsible for the high incidence of cardiovascular complications in CKD patients. Hypolipidemic drugs and low fat diet may be helpful in impeding the progression of cardiovascular complications and decrease mortality and morbidity in those patients.

Entities:  

Keywords:  Cardiovascular complications; Dyslipidemia; Haemodialysis; Hypertriglyceridemia

Year:  2017        PMID: 28273960      PMCID: PMC5324405          DOI: 10.7860/JCDR/2017/24172.9220

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  19 in total

1.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

2.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

Authors:  Michael Miller; Neil J Stone; Christie Ballantyne; Vera Bittner; Michael H Criqui; Henry N Ginsberg; Anne Carol Goldberg; William James Howard; Marc S Jacobson; Penny M Kris-Etherton; Terry A Lennie; Moshe Levi; Theodore Mazzone; Subramanian Pennathur
Journal:  Circulation       Date:  2011-04-18       Impact factor: 29.690

Review 3.  Lipids and renal disease.

Authors:  Roberto Trevisan; Alessandro R Dodesini; Giuseppe Lepore
Journal:  J Am Soc Nephrol       Date:  2006-04       Impact factor: 10.121

Review 4.  Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.

Authors:  N D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2006-02

5.  Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure.

Authors:  N D Vaziri; K Liang; J S Parks
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

6.  Dyslipidemia and cardiovascular risk: the importance of early prevention.

Authors:  M Miller
Journal:  QJM       Date:  2009-06-04

7.  Lipid profile in pre-dialysis chronic kidney disease patients attending University of Maiduguri Teaching Hospital, Maiduguri-Nigeria.

Authors:  D S Mshelia; L B Buratai; Y P Mamza
Journal:  Niger J Clin Pract       Date:  2009-06       Impact factor: 0.968

Review 8.  Hyperlipidemia as a risk factor for cardiovascular disease.

Authors:  Robert H Nelson
Journal:  Prim Care       Date:  2012-12-04       Impact factor: 2.907

9.  Dyslipidemia associated with chronic kidney disease.

Authors:  Vasilis Tsimihodimos; Zoi Mitrogianni; Moses Elisaf
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

10.  Cardiovascular risk factors among patients with chronic kidney disease attending a tertiary hospital in Uganda.

Authors:  Christopher Babua; Robert Kalyesubula; Emmy Okello; Barbara Kakande; Elias Sebatta; Michael Mungoma; Charles Kiiza Mondo
Journal:  Cardiovasc J Afr       Date:  2015 Jul-Aug       Impact factor: 1.167

View more
  3 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3.

Authors:  Yu-Hsuan Lin; Jiun-Chi Huang; Pei-Yu Wu; Szu-Chia Chen; Yi-Wen Chiu; Jer-Ming Chang; Hung-Chun Chen
Journal:  Oncotarget       Date:  2017-12-14

3.  A Study of Creatinine Level among Patients with Dyslipidemia and Type 2 Diabetes Mellitus using Multilayer Perceptron and Multiple Linear Regression.

Authors:  Farah Muna Mohamad Ghazali; Wan Muhamad Amir W Ahmad; Kumar Chandan Srivastava; Deepti Shrivastava; Nor Farid Mohd Noor; Nurul Asyikin Nizam Akbar; Nor Azlida Aleng; Mohammad Khursheed Alam
Journal:  J Pharm Bioallied Sci       Date:  2021-06-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.